AI assistant
IMAGION BIOSYSTEMS LIMITED — Regulatory Filings 2023
Mar 6, 2023
65092_rns_2023-03-06_8d2d5631-c245-482d-a4db-9eedd3985758.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
IMAGION BIOSYSTEMS LIMITED
(ASX : IBX )
7 March 2023
Correction to Announcement and Offer Booklet
MELBOURNE – Imagion Biosystems ( ASX:IBX, Imagion or the Company ), refers to its announcement of today, titled 'Imagion Secures Growth Funding' ( Announcement ) and 'Entitlement Offer Offer Booklet' released to ASX today ( Offer Booklet ).
1. Announcement
The Company notes that in the third dot point under the heading "Other key terms" in the Announcement, the following words are deleted:
"26,138,956 of these options will be issued under the Company’s 7.1 capacity, with the remainder being subject to shareholder approval."
and replaced with the following:
"14,138,956 of these options will be issued under the Company’s 7.1 capacity, with the remainder being subject to shareholder approval."
2. Offer Booklet
The Company notes that in the note to the table in section 3.1 of the Offer Booklet, the following words are deleted:
"Subject to certain conditions being satisfied, under Mercer's first tranche investment, 22,058,824 Shares, 26,138,956 unlisted options and convertible securities with an aggregate face value of $1,650,000 may be issued to Mercer within 10 business days of 7 March 2023 (with a further 15,995,876 unlisted options which may be issued upon receiving shareholder approval)."
and replaced with:
"Subject to certain conditions being satisfied, under Mercer's first tranche investment, 22,058,824 Shares, 14,138,956 unlisted options and convertible securities with an aggregate face value of $1,650,000 may be issued to Mercer within 10 business days of 7 March 2023 (with a further 27,995,876 unlisted options which may be issued upon receiving shareholder approval)."
-ENDS
Imagion Biosystems Limited ACN 616 305 027 Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystems.com
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Company Secretary of Imagion Biosystems Limited
U.S. Media Contact: Australian Media & Investor Relations: Casie Ost Hannah Howlett, WE Communications [email protected] [email protected] +1-619-693-4428 +61 (0) 450648064
Imagion Biosystems Limited ACN 616 305 027 Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystems.com